Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Begin-Period-Cashflow" stands at 37.82 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2023.
Amgen Inc's third quarter result of 8.03 Billion USD for the item "Begin Period Cashflow" represents a decrease of -8.88 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 8.03 Billion USD for the item "Begin Period Cashflow" represents a decrease of -13.69 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 37.82 Billion USD for the item "Begin Period Cashflow" represents a decrease of -3.26 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -41.54 percent compared to the value the year prior.
The 1 year change in percent is -41.54.
The 3 year change in percent is 19.35.
The 5 year change in percent is 10.32.
The 10 year change in percent is 168.87.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Begin Period Cashflow | 905,699,262,464.00 |
![]() | Johnson & Johnson - Begin Period Cashflow | 486,508,953,600.00 |
![]() | AbbVie Inc - Begin Period Cashflow | 399,570,305,024.00 |
![]() | Roche Holding AG - Begin Period Cashflow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Begin Period Cashflow | 280,205,508,085.11 |